ALX Oncology Holdings Inc expected to post a loss of 89 cents a share - Earnings Preview

ALX Oncology Holdings

24/02/2023 17:24

* ALX Oncology Holdings Inc  ALXO.OQ   ALXO.O  is expected
to show
no change in quarterly revenue when it reports  results on
February 27 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for ALX Oncology
Holdings Inc
is for a loss of 89 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ALX
Oncology
Holdings Inc is $34.5​, above​ its last closing price of $6.97.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.77       -0.77      -0.87     Missed  -12.9
 Jun. 30 2022  -0.64       -0.63      -0.81     Missed  -27.9
 Mar. 31 2022  -0.71       -0.71      -0.60     Beat    15.8​
 Dec. 31 2021  -0.62       -0.62      -0.70     Missed  -13.1
 ​​Sep.        -0.47       -0.48      -0.61     Missed  -28.2
 30 2021                                                
 Jun. 30 2021  -0.43       -0.43      -0.40     Beat    6.5​
 Mar. 31 2021  -0.41       -0.41      -0.35     Beat    15
 Dec. 31 2020  -0.30       -0.35      -0.48     Missed  -35.7
 This summary was machine generated February 24 at 17:24 GMT. 
All figures in US dollars  unless otherwise stated